Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids

Glunicate is evaluated compared to nicotinic acid for effects on aortic atheromatous lesions, lipid parameters and factors involved in thrombosis and haemostasis in rabbits kept on a high-cholesterol diet for 12 weeks, using 2 doses of glunicate (0.17 and 0.69 g/day) and 1 of nicotinic acid (0.6 g/d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 1984-01, Vol.53 (1), p.59-68
Hauptverfasser: Criscuoh, M., Renzetti, A.R., Subissi, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 68
container_issue 1
container_start_page 59
container_title Atherosclerosis
container_volume 53
creator Criscuoh, M.
Renzetti, A.R.
Subissi, A.
description Glunicate is evaluated compared to nicotinic acid for effects on aortic atheromatous lesions, lipid parameters and factors involved in thrombosis and haemostasis in rabbits kept on a high-cholesterol diet for 12 weeks, using 2 doses of glunicate (0.17 and 0.69 g/day) and 1 of nicotinic acid (0.6 g/day). Glunicate afforded dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation, while nicotinic acid hardly had any effect. These effects were completely independent of plasma lipid-lowering action, the plasma levels of all lipids being indistinguishable in all cholesterol-fed groups. In addition to inducing the expected changes in the lipid pattern, the atherogenic diet increased platelet aggregation in response to collagen but not to ADP, prolonged the APTT and lowered the plasma fibrinogen levels. Both glunicate and nicotinic acid counteracted the effects of the diet on platelet aggregation and on APTT, but only glunicate normalised the fibrinogen levels. There was no change in PT or in prostacyclin-like activity release from the mesenteric artery after the diet or diet plus drugs.
doi_str_mv 10.1016/0021-9150(84)90105-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81332986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0021915084901059</els_id><sourcerecordid>81332986</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-78d417248baab9d931c467ee38b3c64e2cb740734844d29f5c809320a3680ee83</originalsourceid><addsrcrecordid>eNp9kcFu1DAQQC0EKtvCH4DkA0LtITCOvYl9qYQqWJBW4gJna-JMukZOsthOK36Cb8bbXe2Riy153sx43jD2RsAHAaL5CFCLyog1XGt1Y0DAujLP2Ero1lRCafWcrc7IS3aZ0i8AUK3QF-yiqaVuQKzY301YJu8wE7_ebriQpjU3fB_nTC4nnnfEMWaKHgN_xBD4EOeRu90cKJXnOVR-6hdHPcfCxjm5UM7sXWFwuqfE_fRUJWLX-cwffd7NS-Y4DKWBn-75PmAakQe_9316xV4MGBK9Pt1X7OeXzz_uvlbb75tvd5-2lVNa5KrVvRJtrXSH2JneSOFU0xJJ3UnXKKpd1ypoZbGg-toMa6fByBpQNhqItLxi7491y6S_lzKKHX1yFAJONC_JaiFlbXRTQHUEXZktRRrsPvoR4x8rwB7WYA-O7cGx1co-rcGakvb2VH_pRurPSSfvJf7uFMfkMAwRJ-fTGTOg1gZkwW6PGBUXD56iTc7TVHT7WPTZfvb__8c_rGikNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81332986</pqid></control><display><type>article</type><title>Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Criscuoh, M. ; Renzetti, A.R. ; Subissi, A.</creator><creatorcontrib>Criscuoh, M. ; Renzetti, A.R. ; Subissi, A.</creatorcontrib><description>Glunicate is evaluated compared to nicotinic acid for effects on aortic atheromatous lesions, lipid parameters and factors involved in thrombosis and haemostasis in rabbits kept on a high-cholesterol diet for 12 weeks, using 2 doses of glunicate (0.17 and 0.69 g/day) and 1 of nicotinic acid (0.6 g/day). Glunicate afforded dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation, while nicotinic acid hardly had any effect. These effects were completely independent of plasma lipid-lowering action, the plasma levels of all lipids being indistinguishable in all cholesterol-fed groups. In addition to inducing the expected changes in the lipid pattern, the atherogenic diet increased platelet aggregation in response to collagen but not to ADP, prolonged the APTT and lowered the plasma fibrinogen levels. Both glunicate and nicotinic acid counteracted the effects of the diet on platelet aggregation and on APTT, but only glunicate normalised the fibrinogen levels. There was no change in PT or in prostacyclin-like activity release from the mesenteric artery after the diet or diet plus drugs.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/0021-9150(84)90105-9</identifier><identifier>PMID: 6238601</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Animals ; Aorta ; Aorta - drug effects ; Arteriosclerosis - prevention &amp; control ; Biological and medical sciences ; Blood Coagulation - drug effects ; Cholesterol fed rabbit ; Cholesterol, Dietary - administration &amp; dosage ; Dose-Response Relationship, Drug ; Epoprostenol - metabolism ; General and cellular metabolism. Vitamins ; Glunicate (LG 13979) ; Haemostasis ; Hypercholesterolemia - complications ; Lipids - blood ; Medical sciences ; Niacin - pharmacology ; Niacinamide - analogs &amp; derivatives ; Niacinamide - pharmacology ; Nicotinic acid ; Pharmacology. Drug treatments ; Plasma lipids ; Platelet aggregation ; Platelet Aggregation - drug effects ; Prostacyclin-like activity ; Rabbits</subject><ispartof>Atherosclerosis, 1984-01, Vol.53 (1), p.59-68</ispartof><rights>1984</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-78d417248baab9d931c467ee38b3c64e2cb740734844d29f5c809320a3680ee83</citedby><cites>FETCH-LOGICAL-c481t-78d417248baab9d931c467ee38b3c64e2cb740734844d29f5c809320a3680ee83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0021-9150(84)90105-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=9045903$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6238601$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Criscuoh, M.</creatorcontrib><creatorcontrib>Renzetti, A.R.</creatorcontrib><creatorcontrib>Subissi, A.</creatorcontrib><title>Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Glunicate is evaluated compared to nicotinic acid for effects on aortic atheromatous lesions, lipid parameters and factors involved in thrombosis and haemostasis in rabbits kept on a high-cholesterol diet for 12 weeks, using 2 doses of glunicate (0.17 and 0.69 g/day) and 1 of nicotinic acid (0.6 g/day). Glunicate afforded dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation, while nicotinic acid hardly had any effect. These effects were completely independent of plasma lipid-lowering action, the plasma levels of all lipids being indistinguishable in all cholesterol-fed groups. In addition to inducing the expected changes in the lipid pattern, the atherogenic diet increased platelet aggregation in response to collagen but not to ADP, prolonged the APTT and lowered the plasma fibrinogen levels. Both glunicate and nicotinic acid counteracted the effects of the diet on platelet aggregation and on APTT, but only glunicate normalised the fibrinogen levels. There was no change in PT or in prostacyclin-like activity release from the mesenteric artery after the diet or diet plus drugs.</description><subject>Animals</subject><subject>Aorta</subject><subject>Aorta - drug effects</subject><subject>Arteriosclerosis - prevention &amp; control</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - drug effects</subject><subject>Cholesterol fed rabbit</subject><subject>Cholesterol, Dietary - administration &amp; dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Epoprostenol - metabolism</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Glunicate (LG 13979)</subject><subject>Haemostasis</subject><subject>Hypercholesterolemia - complications</subject><subject>Lipids - blood</subject><subject>Medical sciences</subject><subject>Niacin - pharmacology</subject><subject>Niacinamide - analogs &amp; derivatives</subject><subject>Niacinamide - pharmacology</subject><subject>Nicotinic acid</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasma lipids</subject><subject>Platelet aggregation</subject><subject>Platelet Aggregation - drug effects</subject><subject>Prostacyclin-like activity</subject><subject>Rabbits</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQQC0EKtvCH4DkA0LtITCOvYl9qYQqWJBW4gJna-JMukZOsthOK36Cb8bbXe2Riy153sx43jD2RsAHAaL5CFCLyog1XGt1Y0DAujLP2Ero1lRCafWcrc7IS3aZ0i8AUK3QF-yiqaVuQKzY301YJu8wE7_ebriQpjU3fB_nTC4nnnfEMWaKHgN_xBD4EOeRu90cKJXnOVR-6hdHPcfCxjm5UM7sXWFwuqfE_fRUJWLX-cwffd7NS-Y4DKWBn-75PmAakQe_9316xV4MGBK9Pt1X7OeXzz_uvlbb75tvd5-2lVNa5KrVvRJtrXSH2JneSOFU0xJJ3UnXKKpd1ypoZbGg-toMa6fByBpQNhqItLxi7491y6S_lzKKHX1yFAJONC_JaiFlbXRTQHUEXZktRRrsPvoR4x8rwB7WYA-O7cGx1co-rcGakvb2VH_pRurPSSfvJf7uFMfkMAwRJ-fTGTOg1gZkwW6PGBUXD56iTc7TVHT7WPTZfvb__8c_rGikNg</recordid><startdate>19840101</startdate><enddate>19840101</enddate><creator>Criscuoh, M.</creator><creator>Renzetti, A.R.</creator><creator>Subissi, A.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19840101</creationdate><title>Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids</title><author>Criscuoh, M. ; Renzetti, A.R. ; Subissi, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-78d417248baab9d931c467ee38b3c64e2cb740734844d29f5c809320a3680ee83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Animals</topic><topic>Aorta</topic><topic>Aorta - drug effects</topic><topic>Arteriosclerosis - prevention &amp; control</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - drug effects</topic><topic>Cholesterol fed rabbit</topic><topic>Cholesterol, Dietary - administration &amp; dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Epoprostenol - metabolism</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Glunicate (LG 13979)</topic><topic>Haemostasis</topic><topic>Hypercholesterolemia - complications</topic><topic>Lipids - blood</topic><topic>Medical sciences</topic><topic>Niacin - pharmacology</topic><topic>Niacinamide - analogs &amp; derivatives</topic><topic>Niacinamide - pharmacology</topic><topic>Nicotinic acid</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasma lipids</topic><topic>Platelet aggregation</topic><topic>Platelet Aggregation - drug effects</topic><topic>Prostacyclin-like activity</topic><topic>Rabbits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Criscuoh, M.</creatorcontrib><creatorcontrib>Renzetti, A.R.</creatorcontrib><creatorcontrib>Subissi, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Criscuoh, M.</au><au>Renzetti, A.R.</au><au>Subissi, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>1984-01-01</date><risdate>1984</risdate><volume>53</volume><issue>1</issue><spage>59</spage><epage>68</epage><pages>59-68</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Glunicate is evaluated compared to nicotinic acid for effects on aortic atheromatous lesions, lipid parameters and factors involved in thrombosis and haemostasis in rabbits kept on a high-cholesterol diet for 12 weeks, using 2 doses of glunicate (0.17 and 0.69 g/day) and 1 of nicotinic acid (0.6 g/day). Glunicate afforded dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation, while nicotinic acid hardly had any effect. These effects were completely independent of plasma lipid-lowering action, the plasma levels of all lipids being indistinguishable in all cholesterol-fed groups. In addition to inducing the expected changes in the lipid pattern, the atherogenic diet increased platelet aggregation in response to collagen but not to ADP, prolonged the APTT and lowered the plasma fibrinogen levels. Both glunicate and nicotinic acid counteracted the effects of the diet on platelet aggregation and on APTT, but only glunicate normalised the fibrinogen levels. There was no change in PT or in prostacyclin-like activity release from the mesenteric artery after the diet or diet plus drugs.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>6238601</pmid><doi>10.1016/0021-9150(84)90105-9</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0021-9150
ispartof Atherosclerosis, 1984-01, Vol.53 (1), p.59-68
issn 0021-9150
1879-1484
language eng
recordid cdi_proquest_miscellaneous_81332986
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Aorta
Aorta - drug effects
Arteriosclerosis - prevention & control
Biological and medical sciences
Blood Coagulation - drug effects
Cholesterol fed rabbit
Cholesterol, Dietary - administration & dosage
Dose-Response Relationship, Drug
Epoprostenol - metabolism
General and cellular metabolism. Vitamins
Glunicate (LG 13979)
Haemostasis
Hypercholesterolemia - complications
Lipids - blood
Medical sciences
Niacin - pharmacology
Niacinamide - analogs & derivatives
Niacinamide - pharmacology
Nicotinic acid
Pharmacology. Drug treatments
Plasma lipids
Platelet aggregation
Platelet Aggregation - drug effects
Prostacyclin-like activity
Rabbits
title Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T16%3A27%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glunicate%20(LG%2013979)%20protects%20the%20arterial%20wall%20from%20cholesterol-induced%20atherosclerotic%20changes%20in%20the%20rabbit%20without%20affecting%20plasma%20lipids&rft.jtitle=Atherosclerosis&rft.au=Criscuoh,%20M.&rft.date=1984-01-01&rft.volume=53&rft.issue=1&rft.spage=59&rft.epage=68&rft.pages=59-68&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/0021-9150(84)90105-9&rft_dat=%3Cproquest_cross%3E81332986%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81332986&rft_id=info:pmid/6238601&rft_els_id=0021915084901059&rfr_iscdi=true